The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure reagents for the Olink® Signature Q100 system used by its Critical Care Medicine Department (CCMD) in Bethesda, Maryland. The procurement involves a sole source purchase from Olink Proteomics Inc. for specific reagents essential for studying protein biomarkers in patient samples, as only Olink's products are compatible with the system and critical for ongoing research. Interested parties capable of providing similar products may submit a capability statement by June 20, 2025, to Tasha Lowe at lowet2@mail.nih.gov, as this acquisition is being conducted under simplified acquisition procedures with no set-aside for competition.